AstraZeneca and Targacept: Global Collaboration and License Agreement for TC-5214 for the Treatment of Major Depressive Disorder
07-Dec-2009 -
AstraZeneca and Targacept, Inc. announced a collaboration and license agreement for the global development and commercialization of TC-5214, Targacept’s late-stage investigational product for major depressive disorder (MDD). TC-5214, which recently completed a phase IIb clinical trial, is a ...
AstraZeneca
clinical trials
depressions
+3